A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors

Simultaneous inhibition of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) with bispecific antibodies may improve efficacy over single-agent treatment while limiting toxicity. Cadonilimab is a humanized, bispecific antibody targeting PD-1 and CTLA-4. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Frentzas, Sophia, Gan, Hui K., Cosman, Rasha, Coward, Jermaine, Tran, Ben, Millward, Michael, Zhou, Yiting, Wang, Wenjing, Xia, Dennis, Wang, Zhongmin Maxwell, Li, Baiyong, Xia, Michelle, Desai, Jayesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694581/
https://www.ncbi.nlm.nih.gov/pubmed/37852261
http://dx.doi.org/10.1016/j.xcrm.2023.101242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694581/
https://www.ncbi.nlm.nih.gov/pubmed/37852261
http://dx.doi.org/10.1016/j.xcrm.2023.101242

Ejemplares similares